John Strickler, MD, and team's milestone work on the clinical trial "MOUNTAINEER" has led to the first FDA-approved treatment regimen for HER2+ metastatic colorectal cancer.
The hybrid retreat showcased the latest gastric cancer, blood cancer, pediatric sarcoma, glioblastoma, breast cancer, and immune micro-environment research.
The 2022 Shingleton Society dinner honored four awardees for their service in advancing the fight against cancer and paid video tribute to Cancer Center founder William Shingleton, MD.
The Radiation Research Society bestowed its highest honor — the Failla Memorial Lecture Award — on Michael B. Kastan, MD, PhD, executive director of DCI.
"Just ASK," a course developed and piloted at DCI by Nadine Barrett, PhD, to help improve equity, diversity, and inclusion in cancer clinical trials, has gone national.
A research team led by Ann Marie Pendergast, PhD, found, in animal studies, that a leukemia drug disrupted HER2-positive breast cancer-spread to the brain.
The Division of Nuclear Medicine and Radiotheranostics was named a Comprehensive Radiopharmaceutical Therapy Center of Excellence; one of only 14 in the U.S.
Duke University Hospital in Durham ranks #22 on the list of Best Hospitals for Cancerin the nation and has the highest ranked cancer program in the Southeastern U.S.
The Preston Robert Tisch Brain Tumor Center kicked off Brain Tumor Awareness Month (May) on April 30 with their first full-scale Angels Among Us event since the pandemic began.
Clinical providers, researchers, staff & health leaders came together to celebrate the 50th anniversary of the Duke Comprehensive Cancer Center (now DCI).